Progress Software Corporation
US ˙ NasdaqGS ˙ US7433121008

Introduction

This page provides a comprehensive analysis of the known insider trading history of Charles F Jr Wagner. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Charles F Jr Wagner has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:VRTX / Vertex Pharmaceuticals Incorporated EVP & Chief Financial Officer 51,671
US:BRKR / Bruker Corporation EVP & Chief Financial Officer 99,925
US:PRGS / Progress Software Corporation EVP Finance & Admin and CFO 50,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Charles F Jr Wagner. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases PRGS / Progress Software Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in PRGS / Progress Software Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PRGS / Progress Software Corporation Insider Trades
Insider Sales PRGS / Progress Software Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in PRGS / Progress Software Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PRGS / Progress Software Corporation Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Charles F Jr Wagner as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-12 2025-03-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -3,298 51,671 -6.00 500.00 -1,649,000 25,835,500
2025-02-28 2025-02-26 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -4,962 54,969 -8.28 479.61 -2,379,825 26,363,682
2025-02-26 2025-02-24 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -3,310 59,931 -5.23 483.28 -1,599,657 28,963,454
2025-02-19 2025-02-14 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -2,293 63,241 -3.50 463.46 -1,062,714 29,309,674
2025-02-14 2025-02-12 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 6,655 65,534 11.30
2025-02-12 2025-02-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -2,649 58,879 -4.31 467.98 -1,239,679 27,554,194
2025-02-06 2025-02-04 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 7,114 61,528 13.07
2025-02-06 2025-02-04 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 10,262 54,414 23.24
2024-11-13 2024-11-11 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -3,000 44,137 -6.36 518.27 -1,554,810 22,874,883
2024-06-05 2024-06-03 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -3,250 47,137 -6.45 460.00 -1,495,000 21,683,020
2024-05-30 2024-05-28 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -3,250 50,387 -6.06 454.79 -1,478,068 22,915,504
2024-02-27 2024-02-23 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -3,309 53,583 -5.82 431.79 -1,428,793 23,136,604
2024-02-21 2024-02-20 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -2,812 56,892 -4.71 420.58 -1,182,671 23,927,637
2024-02-21 2024-02-16 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -3,750 59,704 -5.91 424.01 -1,590,038 25,315,093
2024-02-13 2024-02-09 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -2,607 63,454 -3.95 422.74 -1,102,083 26,824,544
2024-02-08 2024-02-07 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 7,114 66,061 12.07
2024-02-08 2024-02-06 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 9,440 58,947 19.07
2024-02-08 2024-02-06 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 5,814 49,507 13.31
2024-01-04 2024-01-02 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -3,000 43,693 -6.42 405.00 -1,215,000 17,695,665
2023-11-21 2023-11-20 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -3,000 46,693 -6.04 349.88 -1,049,640 16,336,947
2023-03-28 2023-03-24 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -1,768 49,611 -3.44 305.38 -539,912 15,150,207
2023-03-21 2023-03-17 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -16 51,379 -0.03 301.13 -4,818 15,471,758
2023-03-21 2023-03-17 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -240 51,395 -0.46 299.58 -71,899 15,396,914
2023-03-21 2023-03-17 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -360 51,635 -0.69 298.09 -107,312 15,391,877
2023-03-21 2023-03-17 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -240 51,995 -0.46 296.30 -71,112 15,406,118
2023-03-21 2023-03-17 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -784 52,235 -1.48 295.43 -231,617 15,431,786
2023-03-21 2023-03-17 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -360 53,019 -0.67 294.52 -106,027 15,615,156
2023-03-14 2023-03-13 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -62 53,379 -0.12 296.77 -18,400 15,841,286
2023-03-14 2023-03-13 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -292 53,441 -0.54 295.89 -86,400 15,812,657
2023-03-14 2023-03-13 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -715 53,733 -1.31 294.52 -210,582 15,825,443
2023-03-14 2023-03-13 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -1,153 54,448 -2.07 293.35 -338,233 15,972,321
2023-03-14 2023-03-13 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -420 55,061 -0.76 292.41 -122,812 16,100,387
2023-03-14 2023-03-13 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -24 56,021 -0.04 288.31 -6,919 16,151,415
2023-03-14 2023-03-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -102 56,045 -0.18 294.94 -30,084 16,529,912
2023-03-14 2023-03-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -27 56,147 -0.05 293.61 -7,927 16,485,321
2023-03-14 2023-03-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -185 56,174 -0.33 292.68 -54,146 16,441,006
2023-03-14 2023-03-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -541 56,359 -0.95 291.47 -157,685 16,426,958
2023-03-14 2023-03-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -30 56,900 -0.05 289.44 -8,683 16,469,136
2023-03-14 2023-03-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -327 56,930 -0.57 288.91 -94,474 16,447,646
2023-03-14 2023-03-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -515 57,257 -0.89 287.83 -148,232 16,480,282
2023-03-14 2023-03-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -361 57,772 -0.62 286.64 -103,477 16,559,766
2023-02-28 2023-02-24 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -3,308 58,133 -5.38 289.12 -956,409 16,807,413
2023-02-22 2023-02-17 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -3,750 61,441 -5.75 292.85 -1,098,188 17,992,997
2023-02-14 2023-02-13 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -4,992 65,191 -7.11 298.26 -1,488,914 19,443,868
2023-02-14 2023-02-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -2,707 70,183 -3.71 294.33 -796,751 20,656,962
2023-02-03 2023-02-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 9,440 72,890 14.88
2023-02-03 2023-02-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 10,262 63,450 19.29
2023-02-03 2023-02-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 10,324 53,188 24.09
2022-05-04 2022-05-02 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -3 42,730 -0.01 264.37 -793 11,296,530
2022-05-04 2022-05-02 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -32 42,733 -0.07 262.06 -8,386 11,198,610
2022-05-04 2022-05-02 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -48 42,765 -0.11 261.15 -12,535 11,168,080
2022-05-04 2022-05-02 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -80 42,813 -0.19 259.45 -20,756 11,107,833
2022-05-04 2022-05-02 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -60 42,893 -0.14 258.21 -15,493 11,075,402
2022-05-04 2022-05-02 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -100 42,953 -0.23 257.18 -25,718 11,046,653
2022-05-04 2022-05-02 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -20 43,053 -0.05 254.87 -5,097 10,972,918
2022-05-03 2022-04-29 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -547 43,073 -1.25 276.17 -151,065 11,895,470
2022-04-05 2022-04-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -223 43,620 -0.51 266.68 -59,470 11,632,582
2022-04-05 2022-04-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -536 43,843 -1.21 265.95 -142,549 11,660,046
2022-04-05 2022-04-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -1,142 44,379 -2.51 265.06 -302,699 11,763,098
2022-04-05 2022-04-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -381 45,521 -0.83 263.67 -100,458 12,002,522
2022-04-05 2022-04-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -300 45,902 -0.65 261.42 -78,426 11,999,701
2022-03-21 2022-03-17 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -61 46,202 -0.13 251.05 -15,314 11,599,012
2022-03-21 2022-03-17 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -3,110 46,263 -6.30 250.13 -777,904 11,571,764
2022-02-28 2022-02-24 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -2,189 49,373 -4.25 227.86 -498,786 11,250,132
2022-02-22 2022-02-17 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -3,439 51,562 -6.25 232.51 -799,602 11,988,681
2022-02-14 2022-02-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -2,434 55,001 -4.24 237.74 -578,659 13,075,938
2022-02-03 2022-02-02 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -2,944 57,435 -4.88 250.07 -736,206 14,362,770
2022-02-03 2022-02-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 10,262 60,379 20.48
2022-02-03 2022-02-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 11,628 50,117 30.21
2022-02-03 2022-02-01 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 3,698 38,489 10.63
2021-05-05 2021-04-30 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -547 34,679 -1.55 217.21 -118,814 7,532,626
2021-02-26 2021-02-24 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -547 35,226 -1.53 217.57 -119,011 7,664,121
2021-02-12 2021-02-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -2,365 35,773 -6.20 214.16 -506,488 7,661,146
2021-02-05 2021-02-03 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 11,627 38,138 43.86
2021-02-05 2021-02-03 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 10,324 26,511 63.78
2020-07-14 2020-07-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -260 16,126 -1.59 293.90 -76,414 4,739,431
2020-07-14 2020-07-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -400 16,386 -2.38 292.86 -117,144 4,798,804
2020-07-14 2020-07-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
S - Sale X -40 16,786 -0.24 291.19 -11,648 4,887,915
2020-05-01 2020-04-30 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -547 16,727 -3.17 251.78 -137,724 4,211,524
2020-02-26 2020-02-24 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
F - Taxes -542 17,274 -3.04 239.23 -129,663 4,132,459
2020-02-07 2020-02-05 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 10,323 17,816 137.77
2020-02-07 2020-02-05 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 3,698 7,493 97.44
2019-04-12 2019-04-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy)
A - Award 9,532 9,532
2019-04-12 2019-04-10 4 VRTX VERTEX PHARMACEUTICALS INC / MA
Common Stock
A - Award 3,697 3,697
2015-03-18 2015-03-17 4 BRKR BRUKER CORP
Common Stock
S - Sale -19,000 99,925 -15.98 18.97 -360,493 1,895,907
2014-09-04 2014-08-30 4 BRKR BRUKER CORP
Common stock
F - Taxes -3,062 118,925 -2.51 20.26 -62,036 2,409,420
2014-08-12 2014-08-08 4 BRKR BRUKER CORP
Stock Option (Right to Buy)
A - Award 49,400 49,400
2014-08-12 2014-08-08 4 BRKR BRUKER CORP
Common Stock
A - Award 25,895 121,987 26.95
2014-08-05 2014-08-02 4 BRKR BRUKER CORP
Common Stock
F - Taxes -10,476 96,092 -9.83 22.40 -234,662 2,152,461
2013-09-04 2013-08-30 4 BRKR BRUKER CORP
Stock Option (Right to Buy)
A - Award 46,698 46,698
2013-09-04 2013-08-30 4 BRKR BRUKER CORP
Common Stock
A - Award 25,726 106,568 31.82
2013-08-06 2013-08-02 4 BRKR BRUKER CORP
Common Stock
F - Taxes -7,186 80,842 -8.16 19.93 -143,217 1,611,181
2012-08-15 2012-08-13 4 BRKR BRUKER CORP
Stock Option (Right to Buy)
A - Award 5,000 5,000
2012-08-06 2012-08-02 4 BRKR BRUKER CORP
Common Stock
A - Award 88,028 88,028
2012-01-06 2012-01-05 4 BRKR BRUKER CORP
Stock Option (Right to Buy)
A - Award 6,000 6,000
2011-05-02 2011-04-28 4 PRGS PROGRESS SOFTWARE CORP /MA
Stock Option
A - Award 50,000 50,000
2011-05-02 2011-04-28 4 PRGS PROGRESS SOFTWARE CORP /MA
Stock Option
A - Award 14,000 59,456 30.80 29.64 414,960 1,762,276
2010-08-06 3 BRKR BRUKER CORP
No securities are beneficially owned
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)